Nezavist

Nezavist
Clinical data
Other namesDCUK-OEt; DCUKA ethyl ester; DCUK ethyl carboxylate
Routes of
administration		Oral[1]
Drug classPeripherally selective GABAA receptor positive allosteric modulator
Identifiers
  • ethyl 5,7-dichloro-4-(diphenylcarbamoylamino)quinoline-2-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H19Cl2N3O3
Molar mass480.35 g·mol−1
3D model (JSmol)
  • CCOC(=O)C1=NC2=C(C(=C1)NC(=O)N(C3=CC=CC=C3)C4=CC=CC=C4)C(=CC(=C2)Cl)Cl
  • InChI=1S/C25H19Cl2N3O3/c1-2-33-24(31)22-15-21(23-19(27)13-16(26)14-20(23)28-22)29-25(32)30(17-9-5-3-6-10-17)18-11-7-4-8-12-18/h3-15H,2H2,1H3,(H,28,29,32)
  • Key:UHTVXLVKFPJKMP-UHFFFAOYSA-N

Nezavist, also known as DCUK-OEt, is a peripherally selective GABAA receptor positive allosteric modulator which is under development for the treatment of alcoholism and depressive disorders.[1][2][3][4] It is taken orally.[1] The drug is a positive allosteric modulator (PAM) specifically of the etomidate allosteric site of the GABAA receptor.[4] As it does not cross the blood–brain barrier, Nezavist is peripherally selective and does not directly produce central nervous system effects.[3] Nonetheless, the drug has been found to reduce alcohol self-administration in rodents, perhaps via intestinal stimulation of the vagus nerve.[4] Nezavist is under development by Lohocla Research.[1][2] As of October 2025, it is in phase 1 clinical trials for alcoholism and the preclinical research stage of development for depressive disorders.[1][2]

See also

References

  1. ^ a b c d e "DCUK OEt". AdisInsight. 10 October 2025. Retrieved 18 May 2026.
  2. ^ a b c "Delving into the Latest Updates on Nezavist with Synapse". Synapse. 8 May 2025. Retrieved 18 May 2026.
  3. ^ a b Hoffman PL, de Guglielmo G, Vengeliene V, Kunze W, Lebonville CL, Swinny JD, et al. (March 2026). "Engaging Gut-to-Brain Signalling to Treat Alcohol Use Disorder". Addiction Biology. 31 (3) e70144. doi:10.1111/adb.70144. PMC 13093268. PMID 41879717.
  4. ^ a b c Simeone X, Khom S, Doppler AM, Seidel T, Scholze P, Tabakoff B, et al. (January 2026). "Nezavist (DCUK-OEt) and aminoquinoline analogues interact with the etomidate site and display a complex mode of modulatory action of the GABAA receptor". European Journal of Pharmacology. 1012 178464. doi:10.1016/j.ejphar.2025.178464. PMID 41419089.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.